Unknown

Dataset Information

0

Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.


ABSTRACT: In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we discuss our efforts that led to the identification of a bicyclic template with potent activity against the NS5B polymerase, a critical enzyme on the life cycle of HCV. In continuation of our exploration to improve the stilbene series, the 3,5,6,8-tetrasubstituted quinoline core was identified as replacement of the stilbene moiety. 6-Methoxy-2(1H)-pyridone was identified among several heterocyclic headgroups to have the best potency. Solubility of the template was improved by replacing a planar aryl linker with a saturated pyrrolidine. Profiling of the most promising compounds led to the identification of quinoline 41 (RG7109), which was selected for advancement to clinical development.

SUBMITTER: Talamas FX 

PROVIDER: S-EPMC3954946 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.

Talamas Francisco X FX   Abbot Sarah C SC   Anand Shalini S   Brameld Ken A KA   Carter David S DS   Chen Jun J   Davis Dana D   de Vicente Javier J   Fung Amy D AD   Gong Leyi L   Harris Seth F SF   Inbar Petra P   Labadie Sharada S SS   Lee Eun K EK   Lemoine Remy R   Le Pogam Sophie S   Leveque Vincent V   Li Jim J   McIntosh Joel J   Nájera Isabel I   Park Jaehyeon J   Railkar Aruna A   Rajyaguru Sonal S   Sangi Michael M   Schoenfeld Ryan C RC   Staben Leanna R LR   Tan Yunchou Y   Taygerly Joshua P JP   Villaseñor Armando G AG   Weller Paul E PE  

Journal of medicinal chemistry 20131106 5


In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we discuss our efforts that led to the identification of a bicyclic template with potent activity against the NS5B polymerase, a critical enzyme on the life cycle of HCV. In continuation of our exploration to improve the stilbene series, the 3,5,6,  ...[more]

Similar Datasets

| S-EPMC3007952 | biostudies-literature
| S-EPMC2984033 | biostudies-literature
| S-EPMC2959901 | biostudies-literature
| S-EPMC2969815 | biostudies-literature
| S-EPMC3515257 | biostudies-literature
| S-EPMC2980051 | biostudies-literature
| S-EPMC2979271 | biostudies-literature
| S-EPMC2983158 | biostudies-literature
| S-EPMC4719973 | biostudies-literature
| S-EPMC2979157 | biostudies-literature